Amid continued hospital growth and expansion, ensuring common access to research capabilities and technology across the entire network of a health system is necessary for clinical trial success.
The coronavirus pandemic has shed light on major imbalances within the healthcare system, specifically, the supply and demand of allied health professionals, and the urgent need to invest in community-based care that prioritizes vulnerable populations.
To truly transform healthcare, we must create a connected care journey: delivering care that meets patients where they are, when they need it, and continues to be personalized for them through their entire health journey, wherever that may lead next.
An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.
It will be vital for providers of healthcare to consider whether innovations truly improve people’s lives and make care more efficient, or will they just be another layer on the workflow and take clinicians’ time away from patients.
Healthcare HR professionals—if they haven’t already—must reshape the workplace each and every day by focusing intently and with new eyes on what matters most during this ongoing pandemic: employees.
In a 10-year study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.
Crisis tests a business's culture. It also is a good time to create or strengthen a culture.
In order to navigate the new landscape COVID-19 has brought along with it and connect with consumers who may be feeling confused and stressed out, lesser-known health insurers will need to introduce themselves to this new audience.
Sharing technologies like blockchain could help healthcare institutions establish a consistent, accurate, and trustworthy approach to data collection and dissemination.
The growth of digital twin technology — paired with the transition towards personalized medicine — has left many healthcare industry professionals evaluating the potential of a “patient twin.”
Medical debt can send people into “a spiral of economic disadvantage,” including a lack of stability and security in personal life, housing and work.
The ‘payvider’ model is best suited for health systems that want to double down on value-based care.
Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.
A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia, regardless of age or hair loss severity.
COVID-19 sped up healthcare’s digital transformation. The 20-minute telehealth visit can mean less unpaid time off from work and the difference between seeking care and putting food on the table. Care-at-home programs can reduce the risks associated with hospitalization, such as hospital-acquired infections.
Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.
As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.
Enterprise imaging platforms would enable organizations to consistently and optimally capture, index, manage, store, distribute, view, exchange and analyze all clinical imaging and multimedia content, enhancing patients’ electronic health records.
Spending on the GLP-1 class of therapeutics is expected to grow by 378% to $8.1 billion by 2027.
Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.
The FDA rejected Humanigen’s application for an emergency use authorization, but the race is on to develop an effective therapy for the cytokine storms that affect patients with COVID-19.
Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.
Organizations setting up hospital-at-home programs need to be aware of the associated risks and mitigation best practices.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
Engaging with payers in collaborative arrangements is critical for achieving quality outcomes at lower cost, while ensuring financial health for providers during good times and bad.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.